Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel dopamine receptor 3 antagonists inhibit the growth of primary and temozolomide resistant glioblastoma cells

4 May 2021

Abstract excerpt

Treatment for the lethal primary adult brain tumor glioblastoma (GBM) includes the chemotherapy temozolomide (TMZ), but TMZ resistance is common and correlates with promoter methylation of the DNA repair enzyme O-6-methylguanine-DNA methyltransferase (MGMT). To improve treatment of GBMs, including those resistant to TMZ, we explored the potential of targeting dopamine receptor signaling. We found that dopamine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Metastases and Treatment
Share to Glioma Diagnosis and Treatment
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33945569
DOI: 10.1371/journal.pone.0250649

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel dopamine receptor 3 antagonists inhibit the growth of primary and temozolomide resistant glioblastoma cellsPMID 33945569Read ↗

Synergistic Effects of the DRD2/3 Antagonist ONC201 and Radiation in GlioblastomaSemantic proximity Read ↗

Dopamine receptor D2 regulates glioblastoma survival and death through MET and death receptor 4/5Semantic proximity Read ↗

A Molecular Screening Approach to Identify and Characterize Inhibitors of Glioblastoma Stem CellsSemantic proximity Read ↗

Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastomaSemantic proximity Read ↗

The Dopamine Receptor Antagonist TFP Prevents Phenotype Conversion and Improves Survival in Mouse Models of GlioblastomaSemantic proximity Read ↗

Development and Characterization of Triazole-Based WDR5 Inhibitors for the Treatment of GlioblastomaSemantic proximity Read ↗

Ribonucleotide Reductase Regulatory Subunit M2 as a Driver of Glioblastoma TMZ-Resistance through Modulation of dNTP ProductionSemantic proximity Read ↗

Inhibition of Metabotropic Glutamate Receptor III facilitates sensitization to alkylating chemotherapeutics in GlioblastomaSemantic proximity Read ↗

Activation of dopamine receptor 2 (DRD2) prompts transcriptomic and metabolic plasticity in glioblastomaSemantic proximity Read ↗

Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitorsSemantic proximity Read ↗

Novel Imidazotetrazine Evades Known Resistance Mechanisms and Is Effective against Temozolomide-Resistant Brain Cancer in Cell CultureSemantic proximity Read ↗

The Dopamine D2 Receptor Contributes to the Spheroid Formation Behavior of U87 Glioblastoma Cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.